• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

发现一系列 2-苯基-N-(2-(吡咯烷-1-基)苯基)乙酰胺作为新型分子开关,调节 K(v)7.2(KCNQ2)通道药理学模式:鉴定出(S)-2-苯基-N-(2-(吡咯烷-1-基)苯基)丁酰胺(ML252)作为一种有效的、可穿透血脑屏障的 K(v)7.2 通道抑制剂。

Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor.

机构信息

Department of Pharmacology, Vanderbilt University Medical Center , Nashville, Tennessee 37232, United States.

出版信息

J Med Chem. 2012 Aug 9;55(15):6975-9. doi: 10.1021/jm300700v. Epub 2012 Jul 26.

DOI:10.1021/jm300700v
PMID:22793372
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3530927/
Abstract

A potent and selective inhibitor of KCNQ2, (S)-5 (ML252, IC(50) = 69 nM), was discovered after a high-throughput screen of the MLPCN library was performed. SAR studies revealed a small structural change (ethyl group to hydrogen) caused a functional shift from antagonist to agonist activity (37, EC(50) = 170 nM), suggesting an interaction at a critical site for controlling gating of KCNQ2 channels.

摘要

一种强效且选择性的 KCNQ2 抑制剂 (S)-5(ML252,IC50 = 69 nM)是通过高通量筛选 MLPCN 文库发现的。构效关系研究表明,一个微小的结构变化(乙基变为氢)导致其功能从拮抗剂转变为激动剂活性(37,EC50 = 170 nM),这表明其在控制 KCNQ2 通道门控的关键部位存在相互作用。

相似文献

1
Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor.发现一系列 2-苯基-N-(2-(吡咯烷-1-基)苯基)乙酰胺作为新型分子开关,调节 K(v)7.2(KCNQ2)通道药理学模式:鉴定出(S)-2-苯基-N-(2-(吡咯烷-1-基)苯基)丁酰胺(ML252)作为一种有效的、可穿透血脑屏障的 K(v)7.2 通道抑制剂。
J Med Chem. 2012 Aug 9;55(15):6975-9. doi: 10.1021/jm300700v. Epub 2012 Jul 26.
2
Identification of a novel, small molecule inhibitor of KCNQ2 channels新型KCNQ2通道小分子抑制剂的鉴定
3
Selective antagonists of mouse trace amine-associated receptor 1 (mTAAR1): discovery of EPPTB (RO5212773).选择性的小鼠痕迹胺相关受体 1(mTAAR1)拮抗剂:EPPTB(RO5212773)的发现。
Bioorg Med Chem Lett. 2011 Feb 15;21(4):1227-31. doi: 10.1016/j.bmcl.2010.12.075. Epub 2010 Dec 21.
4
Pyrrolidin-3-yl-N-methylbenzamides as potent histamine 3 receptor antagonists.吡咯烷-3-基-N-甲基苯甲酰胺作为强效组胺 3 受体拮抗剂。
Bioorg Med Chem Lett. 2011 Oct 1;21(19):5957-60. doi: 10.1016/j.bmcl.2011.07.061. Epub 2011 Jul 27.
5
Identification of 2-(4-benzyloxyphenyl)-N- [1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]acetamide, an orally efficacious melanin-concentrating hormone receptor 1 antagonist for the treatment of obesity.2-(4-苄氧基苯基)-N-[1-(2-吡咯烷-1-基-乙基)-1H-吲唑-6-基]乙酰胺的鉴定,一种用于治疗肥胖症的口服有效的促黑素细胞激素受体1拮抗剂。
J Med Chem. 2005 Mar 10;48(5):1318-21. doi: 10.1021/jm0490890.
6
Metabolism and pharmacokinetics of a novel Src kinase inhibitor TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and its active N-oxide metabolite TG100855 ([7-(2,6-dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolidin-1-yl)-ethoxy]-phenyl}-amine).新型Src激酶抑制剂TG100435([7-(2,6-二氯苯基)-5-甲基苯并[1,2,4]三嗪-3-基]-[4-(2-吡咯烷-1-基乙氧基)-苯基]-胺)及其活性N-氧化物代谢物TG100855([7-(2,6-二氯苯基)-5-甲基苯并[1,2,4]三嗪-3-基]-{4-[2-(1-氧代-吡咯烷-1-基)乙氧基]-苯基}-胺)的代谢与药代动力学
Drug Metab Dispos. 2007 Jun;35(6):929-36. doi: 10.1124/dmd.106.014290. Epub 2007 Mar 19.
7
Potent antagonists of the Kv1.5 potassium channel: synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides.Kv1.5钾通道的强效拮抗剂:N,N-二异丙基-2-(吡啶-3-基)乙酰胺类似物的合成与评价
Bioorg Med Chem Lett. 2006 Nov 15;16(22):5897-901. doi: 10.1016/j.bmcl.2006.08.054. Epub 2006 Sep 1.
8
Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy.新型N-苯基丁酰胺衍生物作为KCNQ开放剂用于治疗癫痫的设计、合成与评价
Bioorg Med Chem Lett. 2018 Sep 15;28(17):3004-3008. doi: 10.1016/j.bmcl.2018.05.019. Epub 2018 May 16.
9
2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.2-(吡咯烷-1-基)乙基-3,4-二氢异喹啉-1(2H)-酮衍生物作为强效和选择性的组胺 H3 受体拮抗剂。
J Med Chem. 2012 Mar 8;55(5):2452-68. doi: 10.1021/jm300011d. Epub 2012 Feb 28.
10
Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.发现并描述 6-{4-[3-(R)-2-甲基吡咯烷-1-基)丙氧基]苯基}-2H-哒嗪-3-酮(CEP-26401,irdabisant):一种强效、选择性组胺 H3 受体反向激动剂。
J Med Chem. 2011 Jul 14;54(13):4781-92. doi: 10.1021/jm200401v. Epub 2011 Jun 2.

引用本文的文献

1
Phox2b-expressing neurons contribute to breathing problems in Kcnq2 loss- and gain-of-function encephalopathy models.表达 Phox2b 的神经元有助于 Kcnq2 功能丧失和获得性功能脑病模型中的呼吸问题。
Nat Commun. 2023 Dec 5;14(1):8059. doi: 10.1038/s41467-023-43834-7.
2
Chemical modulation of Kv7 potassium channels.Kv7钾通道的化学调节
RSC Med Chem. 2021 Jan 14;12(4):483-537. doi: 10.1039/d0md00328j. eCollection 2021 Apr 28.
3
Therapeutic Antibodies Targeting Potassium Ion Channels.靶向钾离子通道的治疗性抗体。

本文引用的文献

1
Strategic use of plasma and microsome binding to exploit in vitro clearance in early drug discovery.在早期药物发现中,利用血浆和微粒体结合的策略来开发体外清除率。
ACS Med Chem Lett. 2010 Feb 3;1(2):50-3. doi: 10.1021/ml900012h. eCollection 2010 May 13.
2
Discovery, Synthesis, and Structure Activity Relationship of a Series of N-Aryl- bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener.一系列N-芳基-双环[2.2.1]庚烷-2-甲酰胺的发现、合成及构效关系:新型KCNQ2和KCNQ4钾通道开放剂ML213的表征
ACS Chem Neurosci. 2011 Oct 19;2(10):572-577. doi: 10.1021/cn200065b.
3
Handb Exp Pharmacol. 2021;267:507-545. doi: 10.1007/164_2021_464.
4
KCNQ3 is the principal target of retigabine in CA1 and subicular excitatory neurons.KCNQ3 是瑞替加滨在 CA1 和海马下兴奋性神经元中的主要作用靶点。
J Neurophysiol. 2021 Apr 1;125(4):1440-1449. doi: 10.1152/jn.00564.2020. Epub 2021 Mar 17.
5
TRPM4 mediates a subthreshold membrane potential oscillation in respiratory chemoreceptor neurons that drives pacemaker firing and breathing.TRPM4 介导呼吸化学感受器神经元中的阈下膜电位振荡,从而驱动起搏放电和呼吸。
Cell Rep. 2021 Feb 2;34(5):108714. doi: 10.1016/j.celrep.2021.108714.
6
An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders.一种基于蒽酮的 Kv7.2/7.3 通道阻断剂,具有改善的性质,可用于研究精神疾病和神经退行性疾病。
Bioorg Med Chem Lett. 2019 Dec 1;29(23):126681. doi: 10.1016/j.bmcl.2019.126681. Epub 2019 Sep 14.
7
Investigation of miscellaneous hERG inhibition in large diverse compound collection using automated patch-clamp assay.使用自动膜片钳测定法对大量不同化合物库中的杂项人乙醚相关基因(hERG)抑制作用进行研究。
Acta Pharmacol Sin. 2016 Jan;37(1):111-23. doi: 10.1038/aps.2015.143.
8
High throughput screening technologies for ion channels.离子通道的高通量筛选技术
Acta Pharmacol Sin. 2016 Jan;37(1):34-43. doi: 10.1038/aps.2015.108. Epub 2015 Dec 14.
9
2013 Philip S. Portoghese Medicinal Chemistry Lectureship: drug discovery targeting allosteric sites.2013年菲利普·S·波托盖斯药物化学讲座:靶向变构位点的药物发现
J Med Chem. 2014 Sep 25;57(18):7485-98. doi: 10.1021/jm5011786. Epub 2014 Sep 15.
10
Drugs for allosteric sites on receptors.作用于受体变构位点的药物。
Annu Rev Pharmacol Toxicol. 2014;54:165-84. doi: 10.1146/annurev-pharmtox-010611-134525. Epub 2013 Oct 2.
The specific slow afterhyperpolarization inhibitor UCL2077 is a subtype-selective blocker of the epilepsy associated KCNQ channels.
特定的慢后超极化抑制剂 UCL2077 是癫痫相关 KCNQ 通道的亚型选择性阻断剂。
Mol Pharmacol. 2010 Dec;78(6):1088-95. doi: 10.1124/mol.110.066100. Epub 2010 Sep 15.
4
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.物理化学空间与最佳口服生物利用度:人体肠道吸收和首过消除的贡献。
J Med Chem. 2010 Feb 11;53(3):1098-108. doi: 10.1021/jm901371v.
5
Cholinergic drugs in pharmacotherapy of Alzheimer's disease.胆碱能药物在阿尔茨海默病药物治疗中的应用
Mini Rev Med Chem. 2002 Feb;2(1):11-25. doi: 10.2174/1389557023406638.
6
2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action.利诺吡啶的2-氟-4-吡啶基甲基类似物作为口服活性乙酰胆碱释放增强剂,具有良好的疗效和作用持续时间。
J Med Chem. 1998 Nov 5;41(23):4615-22. doi: 10.1021/jm9803424.
7
Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine.两种新型强效神经递质释放增强剂,10,10-双(4-吡啶基甲基)-9(10H)-蒽酮和10,10-双(2-氟-4-吡啶基甲基)-9(10H)-蒽酮:与利诺吡啶的比较。
J Pharmacol Exp Ther. 1998 May;285(2):724-30.
8
Single-dose pharmacokinetics, safety, and tolerance of linopirdine (DuP 996) in healthy young adults and elderly volunteers.利诺吡啶(DuP 996)在健康年轻成年人和老年志愿者中的单剂量药代动力学、安全性及耐受性
J Clin Pharmacol. 1995 Jan;35(1):22-30. doi: 10.1002/j.1552-4604.1995.tb04741.x.